Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM On Twitter
  • JABFM On YouTube
  • JABFM On Facebook
Brief ReportBrief Report

Direct-to-Consumer Prescription Drug Advertising and Patient-Provider Interactions

Helen W. Sullivan, Kathryn J. Aikin, Jennifer Berktold, Karen L. Stein and Victoria J. Hoverman
The Journal of the American Board of Family Medicine March 2020, 33 (2) 279-283; DOI: https://doi.org/10.3122/jabfm.2020.02.190278
Helen W. Sullivan
the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn J. Aikin
the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Berktold
the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen L. Stein
the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria J. Hoverman
the US Food and Drug Administration, Silver Spring, MD (HWS, KJA); Westat, Rockville, MD (JB, KLS, VJH).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    Figure 1.

    National Survey of Health Information and Communication, 2017, data collection flow.

Tables

  • Figures
    • View popup
    Table 1.

    Unweighted Demographic Characteristics of Respondents to the National Survey of Health Information and Communication, 2017 (N = 1,744)

    DemographicNo. of Respondents% of Respondents
    Total1,744100.0
    Age
     18 to 3426215.3
     35 to 5446227.0
     55 to 6441924.5
     65 or older57033.3
    Sex
     Male69140.4
     Female1,01859.6
    Race/Ethnicity
     White, non-Hispanic1,25371.8
     Black, non-Hispanic995.7
     Hispanic1015.8
     Other18310.5
     Refused1086.2
    Education
     Less than high school452.7
     High school diploma or the equivalent28017.0
     Some college but not degree35421.5
     Associate degree in college18311.1
     Bachelor’s degree45627.7
     Advanced or postgraduate degree32719.9
    Have prescription drug coverage with health insurance
     Yes1,44887.9
     No1046.3
     No health insurance955.8
    • View popup
    Table 2.

    Questions about Patient-Provider Interactions from the National Survey of Health Information and Communication, 2017 (N = 1,744)

    Question or StatementWeighted Percentage of Answer
    Very UnlikelySomewhat UnlikelyNeither Likely Nor UnlikelySomewhat LikelyVery Likely
    If you saw or heard an ad for a drug that treats a medical condition that was bothering you, how likely would you be to talk to your health care provider about the drug?8.25.69.736.240.3
    If a health care provider refused to prescribe a brand name drug you asked for, how likely would you be to look for a different health care provider?33.415.427.918.05.3
    Disagree stronglyDisagree somewhatNeither agree nor disagreeAgree somewhatAgree strongly
    Ads for prescription drugs help me have better discussions with my health care provider about my health.15.512.238.025.98.4
    Ads for prescription drugs make it seem like a doctor is not needed to decide whether a drug is right for me.22.218.025.022.412.4
    • View popup
    Table 3.

    Questions about Patient-Provider Interactions from the National Survey of Health Information and Communication, 2017 (N = 1,744)

    Question or StatementWeighted Percentage of Answer
    YesNoDo Not Know
    As a result of seeing or hearing an ad for a prescription drug, have you ever talked with a health care provider about a medical condition or illness that you had not talked to a health care provider about before?20.171.18.8
    As a result of seeing or hearing an ad for a prescription drug, have you ever talked with a health care provider about a specific prescription drug you saw or heard advertised?26.170.03.9
    If yes*: Did you specifically ask a health care provider to prescribe the drug you saw or heard advertised?32.563.54.0
    If yes*: Did the health care provider…
     Recommend lifestyle changes, such as getting more exercise or changes in diet.60.0N/AN/A
     Give you a prescription for the drug you saw or heard advertised.16.1N/AN/A
     Give you a prescription for a different drug.21.9N/AN/A
     Not give you any prescription at all.42.6N/AN/A
    Prescription drug advertising has caused me to:
     Talk with my health care provider about symptoms I’ve experienced.34.665.4N/A
     Talk with my health care provider about drug side effects I’ve experienced.27.472.6N/A
     Question the advice of my health care provider.16.084.0N/A
     Experience conflict with a health care provider.4.895.2N/A
    • ↵* These questions were asked of the subset of respondents who answered “yes” to the question “As a result of seeing or hearing an ad for a prescription drug, have you ever talked with a health care provider about a specific prescription drug you saw or heard advertised?” Percentages reflect the weighted proportion of the subset who gave each response.

PreviousNext
Back to top

In this issue

The Journal of the American Board of Family  Medicine: 33 (2)
The Journal of the American Board of Family Medicine
Vol. 33, Issue 2
March/April 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Direct-to-Consumer Prescription Drug Advertising and Patient-Provider Interactions
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Direct-to-Consumer Prescription Drug Advertising and Patient-Provider Interactions
Helen W. Sullivan, Kathryn J. Aikin, Jennifer Berktold, Karen L. Stein, Victoria J. Hoverman
The Journal of the American Board of Family Medicine Mar 2020, 33 (2) 279-283; DOI: 10.3122/jabfm.2020.02.190278

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Direct-to-Consumer Prescription Drug Advertising and Patient-Provider Interactions
Helen W. Sullivan, Kathryn J. Aikin, Jennifer Berktold, Karen L. Stein, Victoria J. Hoverman
The Journal of the American Board of Family Medicine Mar 2020, 33 (2) 279-283; DOI: 10.3122/jabfm.2020.02.190278
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Notes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Most Frequently Read Articles of 2020
  • Many Family Medicine Successful Interventions and Clinical Reviews for Common Illnesses
  • Google Scholar

More in this TOC Section

  • A Case of Extra-Articular Coccidioidomycosis in the Knee of a Healthy Patient
  • The Prevalence of Low-Value Prostate Cancer Screening in Primary Care Clinics: A Study Using the National Ambulatory Medical Care Survey
  • Telephonic Follow-up and the Risk of Death in Ambulatory Patients with COVID-19
Show more Brief Report

Similar Articles

Keywords

  • Direct-to-Consumer Advertising
  • Health Personnel
  • Patient Care
  • Prescription Drugs
  • Surveys and Questionnaires

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2023 American Board of Family Medicine

Powered by HighWire